Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage
Introduction The advent of mobile stroke units (MSU) provide a golden opportunity to rapidly reverse anticoagulant related intracranial hemorrhage (AC‐ICH) in the pre‐hospital setting. The timely reversal of anticoagulants is crucial in halting hematoma expansion and achieving good clinical outcomes...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Stroke: Vascular and Interventional Neurology |
| Online Access: | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_1.230 |
| _version_ | 1797803550141579264 |
|---|---|
| author | Samer Abdul Kareem Varun Chaubal Mustafa Abdul Kareem Rand Al Subu Eugene Lin Osama Zaidat |
| author_facet | Samer Abdul Kareem Varun Chaubal Mustafa Abdul Kareem Rand Al Subu Eugene Lin Osama Zaidat |
| author_sort | Samer Abdul Kareem |
| collection | DOAJ |
| description | Introduction The advent of mobile stroke units (MSU) provide a golden opportunity to rapidly reverse anticoagulant related intracranial hemorrhage (AC‐ICH) in the pre‐hospital setting. The timely reversal of anticoagulants is crucial in halting hematoma expansion and achieving good clinical outcomes. It is known that AC‐ICH is associated with higher mortality rate and higher hematoma expansion than spontaneous ICH. Multiple studies showed that rapid reversal of AC‐ICH is associated with better outcomes and more stability of the hematoma size. Studies showed there is delay in initiation of therapy and revere the anticoagulants in ICH cases, [1,2}. Here, we report 3 cases of AC‐ICH diagnosed on the MSU with pre‐hospital use of reversal agents. To our knowledge, this is the first case series of Non vitamin K antagonist oral anticoagulants (NOACS) on the MSU. Methods We reviewed the MSU data from May 2016 to December 2020 and those with AC‐ICH were selected. Baseline demographics and clinical presentation were obtained including clinical outcome. Results A total of 3 patients were identified. Patient 1 is a96 year‐oldfemale with history of Atrial fibrillation (AF) that presented with AC‐ICH related to Apixaban and was treated with Prothrombin complex concentrate (PCC). The time of MSU examination to treatment (MSUe‐T) was 41 minutes.The patient was neurologically intact and discharged home after 4 days, no further images were indicated as the patient was stable and back to baseline. Patient 2 is a68 year‐oldmale with history of deep vein thrombosis that presented with AC‐ICH related to Warfarin and was treated with PCC. TheMSUe‐T was 64 minutes. Repeated CT head in the ED was stable. Neurological exam improved and the patient discharged to a skilled nursing facility. Patient 3 is a79 year oldmale with history of AF that presented with AC‐ICH related to Rivaroxaban and was treated with PCC. TheMSUe‐T was 50 minutes. Repeated CT head after 3 days was stable. According to FASTEST trial, the average time from onset to treatment of AC‐ICH was 90–120 min.In this trial, the growth of the ICH during the first hours was associated with increase mortality rate,{3} Conclusions Our data demonstrated that management of AC‐ICH on the MSU is feasible and provides an ample opportunity to reverse AC in the hyper‐early stage of ICH. MSU might have an important role in reducing the mortality for AC‐ICH patients. Larger comparative studies between Emergency department and MSU are needed. |
| first_indexed | 2024-03-13T05:22:31Z |
| format | Article |
| id | doaj.art-af234b8622614db382e5e7376b126d62 |
| institution | Directory Open Access Journal |
| issn | 2694-5746 |
| language | English |
| last_indexed | 2024-03-13T05:22:31Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stroke: Vascular and Interventional Neurology |
| spelling | doaj.art-af234b8622614db382e5e7376b126d622023-06-15T10:40:49ZengWileyStroke: Vascular and Interventional Neurology2694-57462023-03-013S110.1161/SVIN.03.suppl_1.230Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial HemorrhageSamer Abdul Kareem0Varun Chaubal1Mustafa Abdul Kareem2Rand Al Subu3Eugene Lin4Osama Zaidat5Henry Ford Health System Detroit Michigan United States of AmericaMercy St Vincent Medical Center Toledo Ohio United States of AmericaAlexandria University‐Faculty of Medicine Alexandria EgyptAnnajah National University Detroit United States of AmericaMercy St Vincent Medical Center Toledo Ohio United States of AmericaMercy St Vincent Medical Center Toledo Ohio United States of AmericaIntroduction The advent of mobile stroke units (MSU) provide a golden opportunity to rapidly reverse anticoagulant related intracranial hemorrhage (AC‐ICH) in the pre‐hospital setting. The timely reversal of anticoagulants is crucial in halting hematoma expansion and achieving good clinical outcomes. It is known that AC‐ICH is associated with higher mortality rate and higher hematoma expansion than spontaneous ICH. Multiple studies showed that rapid reversal of AC‐ICH is associated with better outcomes and more stability of the hematoma size. Studies showed there is delay in initiation of therapy and revere the anticoagulants in ICH cases, [1,2}. Here, we report 3 cases of AC‐ICH diagnosed on the MSU with pre‐hospital use of reversal agents. To our knowledge, this is the first case series of Non vitamin K antagonist oral anticoagulants (NOACS) on the MSU. Methods We reviewed the MSU data from May 2016 to December 2020 and those with AC‐ICH were selected. Baseline demographics and clinical presentation were obtained including clinical outcome. Results A total of 3 patients were identified. Patient 1 is a96 year‐oldfemale with history of Atrial fibrillation (AF) that presented with AC‐ICH related to Apixaban and was treated with Prothrombin complex concentrate (PCC). The time of MSU examination to treatment (MSUe‐T) was 41 minutes.The patient was neurologically intact and discharged home after 4 days, no further images were indicated as the patient was stable and back to baseline. Patient 2 is a68 year‐oldmale with history of deep vein thrombosis that presented with AC‐ICH related to Warfarin and was treated with PCC. TheMSUe‐T was 64 minutes. Repeated CT head in the ED was stable. Neurological exam improved and the patient discharged to a skilled nursing facility. Patient 3 is a79 year oldmale with history of AF that presented with AC‐ICH related to Rivaroxaban and was treated with PCC. TheMSUe‐T was 50 minutes. Repeated CT head after 3 days was stable. According to FASTEST trial, the average time from onset to treatment of AC‐ICH was 90–120 min.In this trial, the growth of the ICH during the first hours was associated with increase mortality rate,{3} Conclusions Our data demonstrated that management of AC‐ICH on the MSU is feasible and provides an ample opportunity to reverse AC in the hyper‐early stage of ICH. MSU might have an important role in reducing the mortality for AC‐ICH patients. Larger comparative studies between Emergency department and MSU are needed.https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_1.230 |
| spellingShingle | Samer Abdul Kareem Varun Chaubal Mustafa Abdul Kareem Rand Al Subu Eugene Lin Osama Zaidat Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage Stroke: Vascular and Interventional Neurology |
| title | Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage |
| title_full | Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage |
| title_fullStr | Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage |
| title_full_unstemmed | Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage |
| title_short | Abstract Number ‐ 230: Mobile Stroke Unit Experience With Anticoagulant Related Intracranial Hemorrhage |
| title_sort | abstract number 230 mobile stroke unit experience with anticoagulant related intracranial hemorrhage |
| url | https://www.ahajournals.org/doi/10.1161/SVIN.03.suppl_1.230 |
| work_keys_str_mv | AT samerabdulkareem abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage AT varunchaubal abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage AT mustafaabdulkareem abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage AT randalsubu abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage AT eugenelin abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage AT osamazaidat abstractnumber230mobilestrokeunitexperiencewithanticoagulantrelatedintracranialhemorrhage |